Hereditary amyloidosis
MONDO:0018634Hereditary amyloidosis refers to a group of inherited conditions that make up one of the subtypes of amyloidosis. Hereditary amyloidosisis characterized by the deposit of an abnormal protein called amyloid in multiple organs of the body where it should not be, which causes disruption of organ tissue structure and function. In hereditary amyloidosis, amyloid deposits most often occur in tissues of the heart, kidneys, and nervous system. While symptoms of hereditary amyloidosis may appear in childhood, most individuals do not experience symptoms until adulthood. There are many types of hereditary amyloidosis associated with different gene mutations and abnormal proteins. The most common type of hereditary amyloidosis is transthyretin amyloidosis (ATTR),a condition in which the amyloid deposits are most often made up of the transthyretin protein which is made in the liver. Other examplesof hereditary amyloidosis include, but are not limited to, apolipoprotein AI amyloidosis (A ApoAI), gelsolin amyloidosis (A Gel), lysozyme amyloidosis (A Lys), cystatin C amyloidosis (A Cys), fibrinogen Aα-chain amyloidosis (A Fib), and apolipoprotein AII amyloidosis (A ApoAII). Most types of hereditary amyloidosis are inherited in an autosomal dominant manner. Treatment is focused on addressing symptoms of organ damage and slowing down the production of amyloid when possible through methods such as liver transplants.
Also known as: amyloidosis, Familial, hereditary amyloidosis (disease), amyloidosis hereditary, familial amyloidosis
82 clinical trials for this condition and its sub-types, 19 tagged with Hereditary amyloidosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hereditary amyloidosis
-
Familial amyloid neuropathy 52 trials · 54 incl. sub-types
4 sub-types
- Amyloidosis, hereditary systemic 1 0 trials · 10 incl. sub-types Sub-types →
- Amyloidosis, hereditary systemic 3 0 trials
- Amyloidosis, hereditary systemic 5 0 trials
- Amyloidosis, hereditary systemic 6 0 trials
-
Cerebral amyloid angiopathy 16 trials · 17 incl. sub-types
4 sub-types
- ACys amyloidosis 1 trial
- Cerebral amyloid angiopathy, APP-related 0 trials · 1 incl. sub-types Sub-types →
- ABri amyloidosis 0 trials
- ADan amyloidosis 0 trials
-
APP-related brain and vascular amyloidosis 0 trials · 5 incl. sub-types
2 sub-types
- Alzheimer disease type 1 4 trials
- Cerebral amyloid angiopathy, APP-related 0 trials · 1 incl. sub-types Sub-types →
-
3 sub-types
-
Finnish type amyloidosis 0 trials
-
ITM2B amyloidosis 0 trials
2 sub-types
- ABri amyloidosis 0 trials
- ADan amyloidosis 0 trials
-
Familial visceral amyloidosis 0 trials
4 sub-types
- AApoAI amyloidosis 0 trials
- AFib amyloidosis 0 trials
- ALys amyloidosis 0 trials
- Apolipoprotein A-II amyloidosis 0 trials
-
Pulmonary amyloidosis 0 trials
-
Variant ABeta2M amyloidosis 0 trials
Most studied deeper sub-types
-
Gene-Editing shot aims to halt rare nerve disease in phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests a single dose of NTLA-2001, a gene-editing therapy, in 60 adults with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare genetic disease that damages nerves. Participants are randomly assigned to receive either the active treatmen…
Phase 3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Gene-Editing breakthrough: could a single dose stop a deadly heart condition?
Disease control Recruiting nowThis study tests a single dose of NTLA-2001, a gene-editing therapy, in 1200 adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a condition where abnormal protein builds up in the heart. The goal is to see if it reduces heart-related deaths and events compared t…
Phase 3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Massive ATTR amyloidosis study aims to map disease journeys
Knowledge-focused Recruiting nowThis observational study will analyze medical records from over 52,000 people with ATTR amyloidosis, a rare disease where abnormal proteins build up in organs. Researchers want to learn about patients' symptoms, treatments, and outcomes in everyday medical practice. No new treatm…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
New study tracks pregnancy safety of rare disease drug
Knowledge-focused Recruiting nowThis study monitors pregnancy outcomes in women who took patisiran-LNP for hereditary ATTR amyloidosis. Researchers will track birth defects, pregnancy complications, and infant health. The goal is to better understand the drug's safety during pregnancy, not to test a new treatme…
Sponsor: Alnylam Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Massive global study aims to unlock secrets of rare heart and nerve disease
Knowledge-focused Recruiting nowThis observational study will follow 1,500 people with ATTR amyloidosis, a rare disease that damages the heart and nerves, for many years. Researchers will track how the disease progresses, how patients are treated in real-world settings, and the safety of two approved drugs, pat…
Sponsor: Alnylam Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Hidden heart risk: study aims to catch deadly protein buildup before symptoms start
Knowledge-focused Recruiting nowThis study is looking for early signs of heart amyloidosis in Black adults who carry a specific gene change (V122I TTR) that raises their risk. Researchers will use heart MRI scans and blood tests to detect protein buildup before symptoms appear. The goal is to find ways to diagn…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Massive global study to track rare heart and nerve disease in real life
Knowledge-focused Recruiting nowThis study will follow about 1,850 people with ATTR amyloidosis, a rare disease that affects the heart and nerves. Researchers will collect information on patients' health, treatments, and outcomes over time to better understand the disease and how current therapies work in every…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Nationwide registry aims to crack the code of a rare protein-clogging disease
Knowledge-focused Recruiting nowThis study is a national registry in Hungary that collects medical information from people diagnosed with systemic amyloidosis, a rare disease where abnormal proteins build up in organs. Researchers will look at patient records to understand how the disease starts, how it is diag…
Sponsor: Semmelweis University • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
New italian registry aims to unlock secrets of rare heart disease
Knowledge-focused Recruiting nowThis study is creating a large database of 1,000 people with ATTR amyloidosis, a rare disease that causes abnormal protein buildup in organs. Researchers will collect health information over time to better understand how the disease progresses and to develop tools that help docto…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New study aims to unravel mysteries of rare genetic disease
Knowledge-focused Recruiting nowThis observational study will follow 20 adults with a confirmed genetic mutation for hereditary transthyretin amyloidosis (ATTR), a rare and serious condition that causes abnormal protein buildup in organs. Researchers will conduct thorough medical exams, heart tests, and neurolo…
Sponsor: Hospital de Alta Complejidad en Red • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Blood particles may reveal hidden heart disease
Knowledge-focused Recruiting nowThis study looks at whether tiny particles released by cells into the blood, called extracellular vesicles, can help detect a type of heart disease called ATTR amyloidosis earlier. The disease often goes unnoticed until serious damage occurs. Researchers will compare these partic…
Sponsor: University of Sao Paulo General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC